IJCRT.ORG ISSN : 2320-2882

INTERNATIONAL JOURNAL OF CREATIVE RESEARCH THOUGHTS (IJCRT)

An International Open Access, Peer-reviewed, Refereed Journal

A Review Of Drug Delivery To CNS

[1]Gaurav D. Pawar, [2]Priyanka S. Zendekar, [3]Gajanan S. Sanap, [4]Aniket A. Bankar, [5]Sudarshan A. Chavan

[1]Student, [2]Assistant Professor, [3]Principal, [4]Student, [5]Student

[1]Department of Pharmacy,

[1]Late Bhagirathi Yashwantrao Pathrikar College of Pharmacy, Pathri, Aurangabad, 431001. Maharashtra, India.

Abstract: Brain, the center of the nervous system in all vertebrate, performs the maximum essential role in each function of human body. However, many neurodegenerative diseases, most cancers and infections of the brain become more prevalent as populations become older. In spite of the primary advances in neuroscience, many potential therapeutics are still unable to reach the central nervous system (CNS) because of the blood-brain barrier (BBB) that is shaped by the tight junctions in the capillary endothelium of the vertebrate brain. This effects withinside the capillary wall behaving as a continuous lipid bilayer and preventing the passage of polar and lipid insoluble substances. Several techniques for handing over drugs to the CNS had been advanced to decorate the ability of therapeutic molecules to cross the BBB by modifying the drug itself, or by coupling it to a vector for receptor-mediated, carrier mediated or adsorption-mediated transcytosis. The brain is a sensitive organ, and evolution constructed very efficient methods to protect it. Unfortunately, the same mechanisms that protect it against intrusive chemical compounds also can frustrate therapeutic interventions. Many existing prescription drugs are rendered ineffective withinside the treatment of cerebral illnesses because of our incapability to effectively deliver and maintain them inside the mind. General strategies that could help drug delivery to the brain easily are interestingly and systematically explained in this review.

Keywords **– Central Nervous System; Blood Brain Barrier; Drug Delivery System; Drug Targeting; Nanoparticle.**

I. INTRODUCTION

Despite enormous advances in brain research, brain and central nervous system disorders remain the world's leading cause of disability, and account for more hospitalizations and extended care than almost all different sicknesses combined. The essential problem in drug delivery to brain is the presence of the BBB. Drugs which can be effective against diseases in the CNS and reach the brain through the blood compartment must pass the BBB. In order to develop drugs which penetrate the BBB properly to exhibit the expected CNS therapeutic effects, it is of great significance to apprehend the mechanisms involved in uptake into and efflux from the brain. The characteristic of the BBB is dynamically regulated via way of means of diverse cells present at the extent of the BBB.[1]

This recognition implies higher understanding of the relationship of transport on the BBB to drug structure and physicochemical properties. Despite successful examples of drug transport to the CNS, however only some have reached the phase where they can provide safe and effective human applications. As pharmacological strategies improve, there will be less need for invasive procedures for treating CNS diseases. Considerable strides were made in intravascular transport and neurosurgical invasive procedures to supply therapeutic materials into the brain. This review will show invaluable to researchers interested in the essential feature of the BBB and those in the pharmaceutical industry interested in rational drug design directed at delivering drugs to the brain.

II. BARRIERS TO CNS DELIVERY

The failure of systemically delivered drugs to effectively treat many CNS diseases may be rationalized through considering some of barriers that inhibit drug shipping to the CNS. It is now nicely established that the BBB is a unique membranous barrier that tightly segregates the brain from the circulating blood.[2, 3] The CNS consist blood capillaries which can be structurally different from the blood capillaries in different tissues; those structural variations bring about a permeability barrier among the blood inside brain capillaries and the extracellular fluid in brain tissue. Capillaries of the vertebrate brain and spinal cord lack the small pores that permit rapid motion of solutes from circulation into different organs; those capillaries are coated with a layer of special endothelial cells that lack fenestrations and are sealed with tight junctions. Tight epithelium, similar in nature to this barrier, is also observed in different organs (skin, bladder, colon, and lung).[4]

OThis permeability barrier, comprising, the brain capillary endothelium, is referred to as the BBB. Ependymal cells lining the cerebral ventricles and glial cells are of three types. Astrocytes shape the structural body work for the neurons and manage their biochemical environment. Astrocytes foot strategies or limbs that spread out and abutting one different, encapsulate the capillaries are closely related to the blood vessels to form the BBB. Oligodendrocytes are liable for the formation and protection of the myelin sheath, which surrounds axons and is vital for the fast transmission of action potentials by salutatory conduction. Microglias are blood derived mononuclear macrophages. The tight junctions among endothelial cells results in a very excessive trans-endothelial electric resistance of 1500-2000 Ω.cm2 in comparison to 3-33 Ω.cm2 of different tissues which reduces the aqueous primarily based totally para-cellular diffusion that is located in different organs.[5,6] The BBB also has an additional enzymatic aspect. Solutes

crossing the cell membrane are subsequently exposed to degrading enzymes found in huge numbers in the endothelial cells that incorporate huge densities of mitochondria, metabolically highly active organelles. BBB enzymes additionally recognize and rapidly degrade most peptides, which includes naturally occurring neuropeptides.[7,8]



Fig 1 : Schematic Comparison Between General (Left) and Brain (Right) Capillaries

Finally, the BBB is in addition reinforced via way of means of a excessive concentration of P-glycoprotein (Pgp), active drug-efflux transporter protein withinside the luminal membranes of the cerebral capillary endothelium. This efflux transporter actively eliminates a large variety of drug molecules from the endothelial cell cytoplasm before they move into the brain parenchyma. Figure-1 gives a schematic illustration of some of these BBB properties using a comparison among brain and general capillaries.

III. Strategies for Enhanced CNS Drug Delivery

To circumvent the multitude of barriers inhibiting CNS penetration with the aid of using capability therapeutic agents, numerous drug transport techniques had been developed.[9,10,11,12] These techniques typically fall into one or greater of the following three categories: manipulating drugs, disrupting the BBB and locating alternative routes for drug transport.

1. Drug Manipulations Lipophilic Analogs

CNS penetration is desired by low molecular weight, lack of ionization at physiological pH, and lipophilicity.[13] Delivery of poorly lipid-soluble compounds to the brain requires a few way of having beyond the BBB. There are numerous possible strategies, consisting of temporary osmotic opening of the BBB, exploiting herbal chemical transporters, highdose chemotherapy, or maybe biodegradable implants. But all of those techniques have major limitations: they're invasive procedures, have poisonous facet effects and low efficiency, and aren't sufficiently safe. Heroin, a diacyl derivative of morphine, is a notorious example that crosses the BBB approximately one hundred instances more easily than its parent drug simply by being extra lipophilic. Hence, a possible strategy is to smuggle compounds throughout as their lipophilic precursors. Because drug's lipophilicity correlates so strongly with cerebro-vascular permeability, hydrophobic analogues of small hydrophilic drugs have to extra effectively penetrate the BBB. This strategy has been frequently employed, but the outcomes have regularly been disappointing. The best examples of such tries are the series of lipophilic analogues of nitrosoureas in which a quantitative structural activity relationship (QSAR) study indicated the anti neoplastic activity was inversely proportional to their lipophilicity. This is due to the fact the extra lipophilic analogs turns into much less soluble Involved. For the direct measurement of brain ISF drug concentration, many researchers have found brain microdialysis to be a beneficial technique.[14,15]

Micro-dialysis is a technique of choice withinside the study of in-vivo drug transport across the BBB, based on brain's physiological and anatomical characteristics considering it to be a non-homogeneous compartment. In addition, drug disposition withinside the brain is determined through protein binding, blood flow, BBB transport, and the exchange among brain extracellular fluid (ECF) and brain cells. Nevertheless, intra-cerebral micro-dialysis is an invasive technique: it entails the implantation of a probe, which may also cause tissue trauma, and consequently may also have consequences for BBB function. Therefore it's far important to decide whether intra-cerebral micro-dialysis gives meaningful data on drug delivery across the BBB and drug disposition in the brain. Since thousands of new therapeutic compounds will have to be examined withinside the near future; alternatives to in-vivo test systems must be developed. Thus, in-vitro models that closely mimic the in-vivo system, at least with respect to barrier properties, are in high demand. Blood-brain barrier models now available make use of cerebral capillary endothelium (porcine brain capillary endothelial cells) or choroid plexus epithelial cells (porcine choroid plexus) [16, 17]. Both cell types need serum withinside the growth medium to proliferate. Serum, however, inhibits the formation of tight cell-cell contacts. Withdrawal of serum favors cellular polarity and increases the barrier houses drastically. Both cell types need serum withinside the increase medium to proliferate. Serum, however, inhibits the formation of tight cell-cell contacts. Withdrawal of serum favors cellular polarity and will increase the barrier properties drastically. Electrical resistance is an easy measure of junctional tightness.[16,17,18]

A very sophisticated however highly dependable and reproducible new method is impedance spectroscopy (IS)[19], wherein AC potentials are carried out over a huge frequency range. At a single constant frequency, AC potentials can be carried out and analyzed if only relative changes after substrate application are expected. IS yields information about both conductivity and dielectric constant (capacitance) of the interfacial region of the cell monolayer. Essentially three forms of brain capillary endothelial cell culture are presently utilized by researchers: primary cultures, cell traces and co-culture systems. The limitation of primary cultures has been their better para-cellular permeability, contemplated by the measurement of the electrical resistance throughout the monolayer. Later developments led to the generation of rat, bovine and human immortalized endothelial cells and their use as a replacement for primary cells in in vitro BBB models.[20] However, these cell systems have not been characterized to the same extent as either primarily Passaged cells. The in-vitro BBB model, which include a co-culture of brain capillary endothelial cells on one side of a filter and astrocytes on the other, is currently used. The strong correlation among the in-vivo and invitro values demonstrated that this in-vitro system is an important tool for the investigation of the function of the BBB withinside the transport of vitamins and drugs to the CNS.[21] The essential advantage of this model is the possible rapid evaluation of techniques for achieving drug focused on to the CNS or to appreciate the eventual central toxicity of systemic drug and to elucidate the molecular delivery mechanism of materials across the BBB. The principal advantage of this version is the possible fast evaluation of techniques for achieving drug concentrated on to the CNS or to appreciate the eventual central toxicity of systemic drug and to clarify the molecular transport mechanism of materials throughout the BBB To circumvent the multitude of limitations inhibiting CNS penetration by capability therapeutic agents, numerous drug transport techniques were developed.[22,23,24]

2. Prodrug

Brain uptake of drugs may be improved via prodrug formation.[25] Prodrugs are pharmacologically inactive compounds that result from transient chemical adjustments of biologically energetic species. The chemical alternate is generally designed to enhance a few deficient physicochemical property, which include membrane permeability or water solubility. After administration, the prodrug, via way of means of distinctive feature of its stepped forward characteristics, is introduced towards the receptor site and is maintained there for longer intervals of time. Here it receives converted to the energetic form, generally via a single activating step. For example, esterification or amidation of hydroxy-, amino-, or carboxylic acid- containing drugs, may greatly enhance lipid solubility and, hence, entry into the brain. Once withinside the CNS, hydrolysis of the modifying group will release the energetic compound simple prodrugs suffer from numerous important limitations. Going to extremes at the lipophilic precursor scale, a likely desire for CNS prodrugs is coupling the drug to a lipid moiety, consisting of fatty acid, glyceride or phospholipids. Such prodrug procedures have been explored for a variety of acid-containing drugs, like levodopa, GABA, Niflumic acid, valproate or vigabatrin are coupled to diglycerides or modified diglycerides.[26]

While expanded lipophilicity might also additionally enhance movement throughout the BBB, it additionally has a tendency to increase uptake into different tissues, causing an increased tissue burden. This selectivity in shipping is especially detrimental while potent tablets consisting of steroids or cytotoxic agents are considered, because toxicity is exacerbated at non-target sites. Moreover, while increased lipophilicity may facilitate drug uptake into the CNS, it also complements efflux processes. This can result in poor tissue retention and short organic action. Furthermore, while the simplest metabolism related to a prodrug have to be its conversion to the parent drug, different routes can occur, and the formed metabolites may contribute to the toxicity of the compounds. These effects, this is poor selectivity, poor retention, and the possibility for reactive metabolites, may often conspire to decrease, not to increase, the therapeutic index of medicine masked as prodrugs. On the alternative hand, prodrug procedures that focus on particular membrane transporters have also been explored more recently (chemically) transforming the drug to be delivered so that it can become the situation of a few particular membrane transporter, consisting of the amino acids, peptide or glucose transporters.[27] And lock-in, while modifier functions (F1...Fn) serve as lipophilizers, protect certain features, or fine-tune the vital molecular properties to prevent premature, unwanted metabolic conversions. The CDDS is designed to go through sequential metabolic conversions, disengaging the modifier functions and finally the targetor, after this moiety fulfils its site- or organ-targeting role. Undoubtedly, the concept advanced from the prodrug concept, however became basically extraordinary by the advent of multi-step activation and targetor moieties. Within the existing formalism, one can say that prodrugs include one or greater F moieties for included or more suitable standard delivery, however they do not include T moieties. Brain-focused on chemical delivery structures constitute simply one class of CDDS; however, that is the maximum advanced class. Using the general CDDS idea, a hit deliveries have been executed to the brain, to the eye, and to the lung.[28]

3. Nano-drug Delivery

Higher drug attention at the specified site may be executed by encapsulating the drugs in a suitable carrier system. Carriers such as nanospheres, nanocapsules and micelles are utilized in turning in the drugs to the CNS. The carrier need to be biodegradable (biodegradable polymers include poly lactide-co-glycolide (PLGA) and poly lactic acid (PLA)), should be able to supply the drug at a particular web website online and should have sufficient tensile strength. Carriers should have a sufficient tensile strength to remain in the move for a long period without degradation.[29] Versatility of a nanoparticulate system in terms of physical, chemical and biological modifications, which it provides, lead them to one of the maximum extensively explored system of drug delivery.[30] Smaller size of the drug-loaded nanocarrier system permits them to diffuse via the small pores present withinside the cell membrane. The nanoparticles because of its small length successfully mask the length-limiting properties of the BBB. One of the perfect techniques is to administer the drug by masking its physicochemical characteristics with the aid of using the usage of polymeric nanoparticles. By this method, the unique drug molecule with none amendment may be administered.[31,32] These polymeric nanoparticles are transported throughout BBB through receptor-mediated endocytosis. This form of transportation is mainly outstanding withinside the endothelial cells of brain capillaries. Drugs are connected to nanoparticles by numerous way like adsorption, encapsulation and covalent attachment.



Fig 2 : Types of Nano-drugs

The surface charge, hydrophobicity and size of the nanoparticles influence the distribution of the drug. Drugs below 200 nm are taken up by the endocytosis-mediated transport mechanism. Cellular uptake of definitely charged nanoparticles is higher because of the negative cell surface.[33] Role of surface charge of nanoparticles. Presence of glycoprotein and glycolipid confers a net negative charge on BBB. Hence, any particles which can be negatively charged will be electro statically repelled from entering BBB. These negatively charged particles can enter cell simplest via transport or receptor-mediated process or via endocytosis. Therefore, cationic nanoparticles may be preferred to reap a better and quicker CNS attention.[34]

4. Interstitial Delivery

The maximum direct manner of circumventing the BBB is to supply drugs at once to the brain interstitium. By directing sellers uniquely to an intracranial target, interstitial drug delivery can theoretically yield high CNS drug concentrations with minimal systemic exposure and toxicity. Furthermore, with this strategy, intracranial drug concentrations may be sustained, that is important in treatment with many chemotherapeutic agents. Injections, Catheters, and Pumps Several techniques had been evolved for turning in pills at once to the brain interstitium. One such methodology is the Ommaya reservoir or implantable pump as mentioned in advance below intraventricular/intrathecal route. This technique, however, does acquire truly continuous drug transport. More recently, numerous implantable pumps had been evolved that own numerous blessings over the Ommaya reservoir. This may be implanted subcutaneously and refilled through subcutaneous injection and are able to turning in drugs as a constant infusion over an extended duration of time. Furthermore, the rate of drug transport may be various using outside handheld computer manage units. Currently every of the 3 different pumps to be had for interstitial CNS drug transport operates through a distinct mechanism. The Infusaid pump makes use of the vapour stress of compressed Freon to supply a drug solution at a consistent rate; the MiniMed PIMS system uses a solenoid pumping mechanism, and the Medtronic SynchroMed system provides drugs thru a peristaltic mechanism.

The distribution of small and large drug molecules withinside the brain can be more advantageous through preserving a stress gradient during interstitial drug infusion to generate bulk fluid convection via the brain interstitium.[35] or by growing the diffusion gradient through maximizing the awareness of the infused agent[36] as a complement to simple diffusion. Another current study suggests that the epidural (EPI) transport of morphine encapsulated in multivesicular liposomes (DepoFoam drug shipping machine) produced a sustained clearance of morphine and a extended analgesia, and the consequences recommend that this transport machine is with out significant pathological results on the dose of 10mg/ml morphine after repeated epidural transport in dogs.[37] Biodegradable polymer Wafers, Microspheres and Nanoparticles Though interstitial drug transport to the CNS has had only modest clinical effect, its therapeutic ability may also soon be found out using new advances in polymer technology to modify the aforementioned techniques. Polymeric or lipid based devices that could supply drug molecules at defined (J. Pharma Pharmaceutical Science (www.ualberta.ca/~csps) 6(2):252-273, 2003) 267 rates for particular durations of time are now creating a tremendous

impact in clinical medicine.[38,39] Drug transport at once to the brain interstitium the usage of polyanhydride wafers can circumvent the BBB and release unprecedented levels of drug directly to an intracranial target in a sustained style for extended periods of time.

The fate of a drug introduced to the brain interstitium from the biodegradable polymer wafer was expected through a mathematical model based on –

a) Rates of drug transport via diffusion and fluid convection;
b) Rates of removal from the brain via degradation, metabolism and permeation via capillary networks; and
c) Rates of nearby binding and internalization.[40]

IV. The Drug Delivery in the CNS

There are some strategies and systems explained below.

1) Strategies for CNS Drug Delivery

The important impediment to supply pills into the CNS is the presence of the BBB, which bureaucracy a physiological and pharmacological barrier to the access of healing marketers from the blood stream.[41] To steer clear of the BBB, diverse drug provider structures had been developed. These techniques may be classified as both systemic or neighborhood delivery.

2) Systematic Drug Delivery System

The promising drug providers which have been investigated in systemic transport structures encompass liposomes, polymeric NPs, polymeric micelles, ceramic NPs and dendrimers.[42] However, most effective liposomes and polymeric NPs were broadly exploited in brain drug transport (Garcia-Garcia et al. 2005). Systemic drug transport is carried out via way of means of intravenous or intraperipheral injection and consequently is non-invasive. The drugs may be administered repeatedly as needed. However, systemic administration calls for large dosages to gain therapeutic concentrations on the target site, that may have an effect on non-target tissues and organs. Active targeting may provide a promising way to this problem. In the design of adequate mind delivery systems, essential requirements need to be taken into account: long circulating properties of the carrier and suitable surface characteristics to allow interactions with endothelial cells.[43]

3) Local Drug Delivery System

To reduce systemic side effects and increase the therapeutic effectiveness, selective transport of drugs for the treatment of diseases localized in a particular organ or tissue is desired. Local management of the therapeutic agents from a biocompatible polymeric transport system implanted on the target site affords a promising strategy . This technique is specially suitable for recurrent malignant gliomas, since 89–90% recur within 2cm of the original site of resection . Local drug transport using polymeric implants withinside the CNS avoids the issue of penetration through the BBB, systemic aspect effects and toxicity, peripheral drug inactivation and necessity for modification of the provider surface. The dangers of neighborhood transport are that the dosage can't be adjusted after implantation, the rate of drug release typically decreases with time, repeated implantation can be required for long-time period launch and the implantation surgical procedure is invasive . Care need to be taken in deciding on the right drug transport system for treatment of a particular disease.[44,45] The biocompatible polymers used for local, managed drug transport may be categorized as biodegradable and non-biodegradable. Biodegradable polymers launch their loaded agents as they breakdown to non-toxic products and are removed through the body, whilst the matrix of non-biodegradable polymers stays intact even after all the therapeutic agent has been released.

The non-degradable polymers which are generally used for drug transport consist of ethylene-vinyl acetate copolymers, numerous acrylate-primarily based totally hydrogels and segmented polyurethane (Domb 1995; Sawyer et al. 2006). The number one problem of non-degradable polymers is that the polymer matrix stays completely as a overseas body, constantly stimulating an inflammatory response. The common degradable polymer carriers consist of poly (lactic acid) (PLA), PLGA, (glycolic acid) (PGA), poly (caprolactone), (hydroxybutyrate), (orthoester), poly (phosphazene), polyanhydrides, gelatin, collagen and oxidized cellulose (Domb 1995; Fournier et al. 2003). In the CNS, the maximum widely used biodegradable polymers are PLGA and polyanhydride poly [bis (p-carboxyphenoxy)] propane-sebacic acid (PCPP-SA).[46,47] Studies have proven that the CNS tissue response to PLGA drug carriers is a moderate and non-specific inflammatory response because of the mechanical trauma through implantation, irrespective of the drug provider form or the implantation site. Local injection of PLGA microspheres has been used to deliver anti-tumour agents including mitoxantrone, hemopexin, platelet component four fragment, 5-fluoro-uracil and carboplatin for remedy of brain tumours. This method is likewise used for treatment of neurodegenerative disease. For example, PLGA microspheres have been used to regionally supply neurotransmitters including dopamine and noradrenaline for treatment of Parkinson's disease (McRae & Dahlstrom 1994). In addition, nearby management of PLGA microparticles loaded with nerve boom component (NGF) was proven to protect neurons from excitotoxin-induced lesions and can be a promising strategy for treatment of Huntington's disease.[48,49]

V. Conclusion

The treatment of CNS diseases is mainly challenging due to the fact the transport of drug molecules to the brain is often precluded by lots of physiological, metabolic and biochemical limitations that together include the BBB, BCB and BTB. The present outlook for sufferers suffering from many forms of CNS diseases remains poor, however recent tendencies in drug transport strategies provide reasonable desire that the formidable barriers shielding the CNS may ultimately be overcome. Drug transport at once to the brain interstitium has lately been markedly enhanced through the rational layout of polymer-based drug transport systems. Substantial development will only come about, however, if continued vigorous research efforts to develop greater therapeutic and much less toxic drug molecules are paralleled by the aggressive pursuit of more effective mechanisms for turning in those drugs to their CNS . Each of the strategies has multiple applications in CNS repair. For example, transport of drugs and/or bioactive molecules may be used to treat tumour and neurodegenerative diseases, lessen inflammatory tissue reaction and promote tissue regeneration. Stem cell therapy may be used to deal with neurodegenerative diseases and promote tissue regeneration. Hydrogel scaffolds are often used for helping tissue regeneration withinside the CNS; however, its potential for tumour therapy changed into also explored.

VI. REFERENCES

[1] Pardridge WM. Peptide Drug Delivery to the Brain Raven Press. New York, pp. l-357. 1991.
[2] Begley DJ. The blood-brain barrier: principles for targeting peptides and drugs to the central nervous system. Journal of pharmacy and pharmacology. 1996 Feb;48(2):136-46.
[3] Schlosshauer B, Steuer H. Comparative anatomy, physiology and in vitro models of the blood-brain and blood-retina barrier. Current Medicinal Chemistry-Central Nervous System Agents. 2002 Sep 1;2(3):175-86.
[4] Crone C. The blood-brain barrier: a modified tight epithelium. Ellis Horwood, Chichester; 1986.
[5] Brightman MW. Ultrastructure of brain endothelium. InPhysiology and pharmacology of the blood-brain barrier 1992 (pp. 1-22). Springer, Berlin, Heidelberg.
[6] Lo EH, Singhal AB, Torchilin VP, Abbott NJ. Drug delivery to damaged brain. Brain research reviews. 2001 Dec 1;38(1-2):140-8.
[7] Brownlees J, Williams CH. Peptidases, peptides, and the mammalian blood–brain barrier. Journal of neurochemistry. 1993 Mar;60(3):793-803.
[8] Witt KA, Gillespie TJ, Huber JD, Egleton RD, Davis TP. Peptide drug modifications to enhance bioavailability and blood-brain barrier permeability. Peptides. 2001 Dec 1;22(12):2329-43.
[9] Witt KA, Gillespie TJ, Huber JD, Egleton RD, Davis TP. Peptide drug modifications to enhance bioavailability and blood-brain barrier permeability. Peptides. 2001 Dec 1;22(12):2329-43.
[10] Siegal T, Zylber-Katz E. Strategies for increasing drug delivery to the brain. Clinical pharmacokinetics. 2002 Mar;41(3):171-86.
[11] Habgood MD, Begley DJ, Abbott NJ. Determinants of passive drug entry into the central nervous system. Cellular and molecular neurobiology. 2000 Apr;20(2):231-53.
[12] Filmore D. Breeching the blood-brain barrier. Modern Drug Discovery. 2002;5:22-7.
[13] Pardridge WM. Recent advances in blood-brain barrier transport. Annual review of pharmacology and toxicology. 1988 Apr;28(1):25-39.
[14] Tetsuya T, Yoshiharu D, Yuko K, Pardridge WM, Akira T. Determination of in vivo steady-state unbound drug concentration in the brain interstitial fluid by microdialysis. International journal of pharmaceutics. 1992 Mar 31;81(2-3):143-52.
[15] Menacherry S, Hubert W, Justice JB. In vivo calibration of microdialysis probes for exogenous compounds. Analytical chemistry. 1992 Mar 1;64(6):577-83.
[16] Tewes B, Franke H, Hellwig S, Hoheisel D, Decker S, Griesche D, Tilling T, Wegener J, Galla HJ. Preparation of endothelial cells in primary cultures obtained from the brains of 6-month-old pigs. Drug Transport Across the Blood-Brain-Barrier (BBB): In Vivo and In Vitro Techniques (ed. de Boer and W. Sutano). 1997:91-7.
[17] Gath U, Hakvoort A, Wegener J, Decker S, Galla HJ. Porcine choroid plexus cells in culture: expression of polarized phenotype, maintenance of barrier properties and apical secretion of CSF-components. European journal of cell biology. 1997 Sep;74(1):68-78.
[18] Erben M, Decker S, Franke H, Galla HJ. Electrical resistance measurements on cerebral capillary endothelial cells—a new technique to study small surface areas. Journal of biochemical and biophysical methods. 1995 Nov 1;30(4):227-38.
[19] Wegener J, Sieber M, Galla HJ. Impedance analysis of epithelial and endothelial cell monolayers cultured on gold surfaces. Journal of biochemical and biophysical methods. 1996 Jul 10;32(3):151-70.
[20] Hurst RD, Fritz IB. Properties of an immortalised vascular endothelial/glioma cell co-culture model of the blood-brain barrier. Journal of cellular physiology. 1996 Apr;167(1):81-8.
[21] Dehouck MP, Dehouck B, Schluep C, Lemaire M, Cecchelli R. Drug transport to the brain: comparison between in vitro and in vivo models of the blood-brain barrier. European journal of pharmaceutical sciences. 1995 Dec 1;3(6):357-65.
[22] Habgood MD, Begley DJ, Abbott NJ. Determinants of passive drug entry into the central nervous system. Cellular and molecular neurobiology. 2000 Apr;20(2):231-53.
[23] Thorne RG, Frey WH. Delivery of neurotrophic factors to the central nervous system. Clinical pharmacokinetics. 2001 Dec;40(12):907-46.
[24] Filmore D. Breeching the blood-brain barrier. Modern Drug Discovery. 2002;5:22-7.
[25] Bodor N, Kaminski JJ. Prodrugs and site-specific chemical delivery systems. InAnnual Reports in Medicinal Chemistry 1987 Jan 1 (Vol. 22, pp. 303-313). Academic Press.
[26] Lambert DM. Rationale and applications of lipids as prodrug carriers. European journal of pharmaceutical sciences. 2000 Oct 1;11:S15-27.
[27] Han HK, Amidon GL. Targeted prodrug design to optimize drug delivery. Aaps Pharmsci. 2000 Mar;2(1):48-58.
[28] Bodor N, Buchwald P. Drug targeting via retrometabolic approaches. Pharmacology & therapeutics. 1997 Oct 1;76(1-3):1-27.
[29] Missirlis D, Tirelli N, Hubbell JA. Amphiphilic hydrogel nanoparticles. Preparation, characterization, and preliminary assessment as new colloidal drug carriers. Langmuir. 2005 Mar 15;21(6):2605-13.
[30] Tenzer S, Docter D, Rosfa S, Wlodarski A, Kuharev J, Rekik A, Knauer SK, Bantz C, Nawroth T, Bier C, Sirirattanapan J. Nanoparticle size is a critical physicochemical determinant of the human blood plasma corona: a comprehensive quantitative proteomic analysis. ACS nano. 2011 Sep 27;5(9):7155-67.
[31] Karnovsky MJ. The ultrastructural basis of capillary permeability studied with peroxidase as a tracer. The Journal of cell biology. 1967 Oct 1;35(1):213-36.
[32] Rapoport SI. Effect of concentrated solutions on blood-brain barrier. American Journal of Physiology-Legacy Content. 1970 Jul 1;219(1):270-4.
[33] Andrieux K, Garcia-Garcia E, Kim HR, Couvreur P. Colloidal carriers: a promising way to treat central nervous system diseases. Journal of Nanoneuroscience. 2009 Jun 1;1(1):17-34.
[34] Lockman PR, Koziara JM, Mumper RJ, Allen DD. Nanoparticle surface charges alter blood–brain barrier integrity and permeability. Journal of drug targeting. 2004 Dec 1;12(9-10):635-41.
[35] Bobo RH, Laske DW, Akbasak A, Morrison PF, Dedrick RL, Oldfield EH. Convection-enhanced delivery of macromolecules in the brain. Proceedings of the National Academy of Sciences. 1994 Mar 15;91(6):2076-80.

[36] KrolI RA, Pagel MA, Muldoon LL, Roman-Goldstein S, Neuwelt EA, Neuwelt EA, Neuwelt EA. Increasing Volume of Distribution to the Brain with Interstiti; Infusion: Dose, Rather Than Convection, Might Be the Most Important Factor. Neurosurgery. 1996 Apr 1;38(4):746-54.

[37] Yaksh TL, Provencher JC, Rathbun ML, Myers RR, Powell H, Richter P, Kohn FR. Safety assessment of encapsulated morphine delivered epidurally in a sustained-release multivesicular liposome preparation in dogs. Drug Delivery. 2000 Jan 1;7(1):27-36.

[38] Brem H, Langer R. Polymer-based drug delivery to the brain. Science and medicine. 1996 Jul;3:52-61.

[39] Brem H, Gabikian P. Biodegradable polymer implants to treat brain tumors. Journal of controlled release. 2001 Jul 6;74(1-3):63-7.

[40] Fung LK, Ewend MG, Sills A, Sipos EP, Thompson R, Watts M, Michael Colvin O, Brem H, Saltzman WM. Pharmacokinetics of interstitial delivery of carmustine, 4-hydroperoxycyclophosphamide, and paclitaxel from a biodegradable polymer implant in the monkey brain. Cancer research. 1998 Feb 15;58(4):672-84.

[41] Garcia-Garcia E, Andrieux K, Gil S, Couvreur P. Colloidal carriers and blood–brain barrier (BBB) translocation: a way to deliver drugs to the brain?. International journal of pharmaceutics. 2005 Jul 25;298(2):274-92.

[42] Cherian AK, Rana AC, Jain SK. Self-assembled carbohydrate-stabilized ceramic nanoparticles for the parenteral delivery of insulin. Drug development and industrial pharmacy. 2000 Jan 1;26(4):459-63.

[43] Misra A, Ganesh S, Shahiwala A, Shah SP. Drug delivery to the central nervous system: a review. J Pharm Pharm Sci. 2003 Aug 5;6(2):252-73.

[44] Meilander NJ, Yu X, Ziats NP, Bellamkonda RV. Lipid-based microtubular drug delivery vehicles. Journal of controlled release. 2001 Mar 12;71(1):141-52.

[45] Domb AJ. Polymericcarriers for regional drug therapy. Molecular medicine today. 1995 Jun 1;1(3):134-9.

[46] Sawyer AJ, Piepmeier JM, Saltzman WM. Cancer issue: new methods for direct delivery of chemotherapy for treating brain tumors. The Yale journal of biology and medicine. 2006 Dec;79(3-4):141.

[47] Fournier E, Passirani C, Montero-Menei CN, Benoit JP. Biocompatibility of implantable synthetic polymeric drug carriers: focus on brain biocompatibility. Biomaterials. 2003 Aug 1;24(19):3311-31.

[48] Menei P, Boisdron-Celle M, Croué A, Guy G, Benoit JP. Effect of stereotactic implantation of biodegradable 5-fluorouracil-loaded microspheres in healthy and C6 glioma-bearing rats. Neurosurgery. 1996 Jul 1;39(1):117-24.

[49] Zhong Y, Bellamkonda RV. Biomaterials for the central nervous system. Journal of the Royal Society Interface. 2008 Sep 6;5(26):957-75.